The Shotlee Journal
Browse Shotlee articles about GLP-1 Medications.
Showing 9 / 937 GLP-1 Medications articles
The new FDA-approved Wegovy pill is now available at just $149 per month for starter doses via WeightWatchers Med+, making GLP-1 weight loss therapy more affordable. This self-pay pricing beats typical injectable costs, but it's limited to 1.5mg and 4mg doses for the first four months. Discover eligibility, comparisons, and how to get started before the offer ends April 15.
Why do some people lose remarkable weight on Ozempic while others see minimal results or severe nausea? A new Nature study of nearly 28,000 GLP-1 drug users shows your genes are a key factor. Specific variants in GLP1R and GIPR genes predict both efficacy and side effects, opening doors to personalized prescribing.
With 1 in 8 American adults now taking GLP-1 medications for diabetes or weight loss, pharmacists are key allies in navigating costs, side effects, and long-term success. Experts like Martin Torres, PharmD, emphasize their role in maximizing benefits while minimizing risks. Here are three essential ways they support your GLP-1 experience.
Semaglutide injections like Ozempic have arrived in India at low prices, exciting millions with diabetes and rising obesity. But experts like Dr. Gagandeep Singh caution it's no magic fix—weight returns upon stopping, muscle loss is common, and misuse risks malnutrition. Understand the real story behind these GLP-1 weight loss injections.
US drugmaker Eli Lilly is set to bring orforglipron, a game-changing oral weight-loss pill, to India following successful global trials that included Indian patients. With obesity rates surging, this daily GLP-1 therapy promises easier access than injectables like Mounjaro. Explore the trial data, market insights, and what it means for patients.
A new Stanford Medicine study uncovers why GLP-1 receptor agonists may not work as well for some Type 2 diabetes patients: certain genetic variants lead to GLP-1 resistance. Carried by about 10% of the population, these variants result in higher but less effective GLP-1 levels. This could guide faster, personalized treatment switches.
Ozempic isn't just transforming waistlines—it's igniting a surge in hot sauce sales like Tapatío's. As millions embrace GLP-1 drugs, cravings for bold flavors skyrocket, propelling L.A.'s iconic brand into national expansion under new owners Highlander Partners. This is the untold story of family legacy meeting metabolic health trends.
Scientists have uncovered why Ozempic and similar GLP-1 drugs don't work for everyone: genetic variants in the PAM gene cause GLP-1 resistance in about 10% of people. Despite higher GLP-1 levels, these individuals show reduced drug effectiveness in lowering blood sugar. This breakthrough could pave the way for personalized treatment strategies.
New research reveals a hidden genetic reason why Ozempic fails for some: GLP-1 resistance linked to PAM gene variants affecting 10% of the population. Despite higher GLP-1 levels, these individuals show reduced drug efficacy in lowering blood sugar. Discover the study's findings from humans, mice, and clinical trials.
